Article
Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinoma
2022-03-23
Abstract excerpt
<h4>Background: </h4> TRK tyrosine kinase inhibitors (larotrectinib or entrectinib) can cause an unknown histological response in NTRK fusion-positive cancer patients,and it has been approved by the US Food and Drug Administration.The neurotrophic tyrosine kinase receptor (NTRK) 3 gene rearrangements is a target of tyrosine kinase inhibitors.We attempted to assess the correlation of NTRK3 gene rearrangement and ge...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- db731fa2-0809-54c3-bfcb-a01f8bcad522
- DOI
- 10.21203/rs.3.rs-1387968/v2
